

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

April 10, 2015
Date of Report (Date of Earliest Event Reported)

IntelGenx Technologies Corp.
(Exact Name of Registrant as Specified in its Charter)

Delaware (State or other jurisdiction of incorporation)	000-31187 (Commission File Number)	870638336 (IRS Employer Identification No.)
6425 Abrams, Ville St- Laurent, Quebec, Canada (Address of principal executive offices)		H4S 1X9 (Zip Code)

Registrant's telephone number, including area code: **(514) 331-7440**

Check the appropriate box below if the Form 8K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a -12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
- Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Item 8.01 Other Events - News Release

IntelGenx Founder, President and CEO Dr. Horst Zerbe Interviewed on Fox Business Network's *After the Bell*

Exhibit	Description
99.1	Press Release

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INTELGENX TECHNOLOGIES CORP.

Dated: April 10, 2015

By: /s/ Paul A. Simmons
Paul A. Simmons
Chief Financial Officer

IntelGenx Founder, President and CEO Dr. Horst Zerbe Interviewed on Fox Business Network's *After the Bell*

SAINT LAURENT, QUEBEC , April 10, 2015 - IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) today announced its President and CEO Dr. Horst G. Zerbe, was a guest on FOX Business Network's *After the Bell* (weekdays 4-5PM/ET) on Thursday, April 9, 2015.

During the show, Zerbe discussed the company's growth opportunities for its immediate-release, oral film technology, VersaFilm™. As an example, this technology is effective for the treatment of migraines. A replay of the segment can be found at the following link: <http://video.foxbusiness.com/v/4163821880001>

Dr. Zerbe has more than 30 years' experience in Pharmaceutical R&D, technology management, business development and corporate management. Prior to founding IntelGenx, Dr. Zerbe served as the president of Smatrix Technologies Inc. in Montreal, and as Vice President of R&D at LTS Lohmann Therapy Systems in West Caldwell, NJ. Dr. Zerbe holds more than 40 patents in drug delivery related fields and has published numerous scientific papers in recognized journals.

About IntelGenx:

IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' development pipeline includes products for the treatment of indications such as severe depression, hypertension, erectile dysfunction, migraine, insomnia, CNS indications, idiopathic pulmonary fibrosis, oncology and pain, as well as animal health products. More information is available about the company at www.intelgenx.com.

Each of the TSX Venture Exchange and OTCQX has neither approved nor disapproved the contents of this press release.

CONTACT:

Paul A. Simmons
Chief Financial Officer
IntelGenx Technologies Corp.
T: +1 514-331-7440
F: +1 514-331-0436
www.intelgenx.com
